Clinical and Experimental Hepatology
eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2025
vol. 11
 
Share:
Send email
Share:
Review paper

Recommendations for hypolipidemic and antithrombotic therapy in HCV-infected patients treated with direct-acting antiviral agents: expert position statement

Jerzy Jaroszewicz
1
,
Marlena Broncel
2
,
Anna Piekarska
3
,
Filip M. Szymanski
4
,
Krzysztof Tomasiewicz
5
,
Paweł Rajewski
6
,
Maciej Banach
7, 8
,
Bartosz Hudzik
9, 10
,
Mariusz Gąsior
9
,
Robert Flisiak
11
,
Robert Gil
12

  1. Department of Infectious Diseases and Hepatology, Medical University of Silesia in Katowice, Poland
  2. Department of Internal Medicine and Clinical Pharmacology, Medical University of Lodz, Centre for the Treatment of Lipid Disorders, Łódź, Poland
  3. Department of Infectious Diseases and Hepatology, Medical University of Lodz, Łódź, Poland
  4. Department of Civilization Diseases, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University, Warsaw, Poland
  5. Department of Infectious Diseases and Hepatology, USK-1, Medical University of Lublin, Lublin, Poland
  6. Department of Internal and Infectious Diseases, Provincial Infectious Disease Hospital, Bydgoszcz, Poland
  7. Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Lodz, Poland
  8. Faculty of Medicine, John Paul II Catholic University of Lublin, Lublin, Poland
  9. 3rd Department and Clinical Department of Cardiology, Faculty of Medicine with Division of Medicine and Dentistry in Zabrze, Medical University of Silesia in Katowice, Silesian Center for Heart Diseases, Zabrze, Poland
  10. Department of Cardiovascular Prevention, Faculty of Public Health in Bytom, Medical University of Silesia in Katowice, Poland
  11. Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland
  12. National Medical Institute of the Internal Affairs and Administration Ministry, Warsaw, Poland
Clin Exp HEPATOL 2025; 11, 3: 205–218
DOI: https://doi.org/10.5114/ceh.2025.154978
Online publish date: 2025/09/30
Article file
- Recommendations.pdf  [0.16 MB]
Get citation
 
PlumX metrics:
 
1. Jaroszewicz J, Flisiak R. Metabolic syndrome and hepatitis C infection – brothers in arms. Liver Int 2013; 33: 1135-1137.
2. Leslie J, Geh D, Elsharkawy AM, et al. Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions. 
J Hepatol 2022; 77: 219-236.
3. Dobrowolski P, Prejbisz A, Kuryłowicz A, et al. Metabolic syndrome – a new definition and management guidelines: A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, “Club 30” Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons. Arch Med Sci 2022; 18: 1133-1156.
4. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024; 45: 3415-3537.
5. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023; 44: 3720-3826.
6. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42: 3227-3337.
7. Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023; 44: 4043-4140. Erratum in: Eur Heart J 2023; 44: 5060.
8. Enger C, Forssen UM, Bennett D, et al. Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study. Adv Ther 2014; 31: 891-903.
9. Gutierrez J, Elkind M. Chronic inflammatory diseases and stroke: Evidence for heterogeneous mechanisms. Ann Neurol 2012; 72: S6-S7.
10. Lee KK, Stelzle D, Bing R, et al. Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. Lancet Gastroenterol Hepatol 2019; 4: 794-804.
11. Kcomt W, Nahavandi AA, Myaing M, et al. Hepatitis C and the heart: to beat or not to beat. Int J Cardiol 2004; 96: 147-149.
12. Yang YH, Chiang HJ, Yip HK, et al. Risk of new-onset atrial fibrillation among Asian chronic hepatitis C virus carriers: A nationwide population-based cohort study. J Am Heart Assoc 2019; 8: e012914.
13. Wu VC, Chen TH, Wu M, et al. Risk of cardiac arrhythmias in patients with chronic hepatitis B and C infections – a 13-year nationwide population-based study. J Cardiol 2019; 74: 333-338.
14. Jaroszewicz J, Flisiak R, Dusheiko G. A pill for HCV – myth or foreseeable future? Liver Int 2014; 34: 6-11.
15. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014; 146: 1176-1192.
16. Flisiak R, Zarębska-Michaluk D, Janczewska E, et al. Treatment of HCV infection in Poland at the beginning of the interferon-free era-the EpiTer-2 study. J Viral Hepat 2018; 25: 661-669.
17. Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, et al. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther 2016; 44: 946-956.
18. Tomasiewicz K, Flisiak R, Jaroszewicz J, et al. Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023. Clin Exp Hepatol 2023; 9: 1-8.
19. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188.
20. Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci 2021; 17: 1447-1547.
21. Banach M, Reiner Ž, Surma S, et al. International Lipid Expert Panel (ILEP). 2024 Recommendations on the optimal use of 
lipid-lowering therapy in established atherosclerotic cardiovascular disease and following acute coronary syndromes: A Position paper of the International Lipid Expert Panel (ILEP). Drugs 2024; 84: 1541-1577.
22. Banach M, Penson PE, Vrablik M, et al. Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacol Res 2021; 166: 105499.
23. Weng TC, Yang YH, Lin SJ, et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010; 35: 139-151.
24. Banach M, Surma S, Kapłon-Cieślicka A, et al. Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association. Arch Med Sci 2023; 20: 28-42.
25. Watts GF, Gidding SS, Hegele RA, et al. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat Rev Cardiol 2023; 20: 845-869.
26. Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J 2022; 43: 3213-3223.
27. Rajewski P, Zarębska-Michaluk D, Janczewska E, et al. Hepatitis C infection as a risk factor for hypertension and cardiovascular diseases: An EpiTer Multicenter Study. J Clin Med 2022; 11: 5193.
28. Petta S, Maida M, Macaluso FS, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: A meta-analysis of observational studies. Gastroenterology 2016; 150: 145-155.e4.
29. Schierwagen R, Uschner FE, Magdaleno F, et al. Rationale for the use of statins in liver disease. Am J Physiol Gastrointest Liver Physiol 2017; 312: G407-G412.
30. Pose E, Trebicka J, Mookerjee RP, et al. Statins: Old drugs as new therapy for liver diseases? J Hepatol 2019; 70: 194-202.
31. Kim RG, Loomba R, Prokop LJ, et al. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 1521-1530.e8.
32. Vahedian-Azimi A, Shojaie S, Banach M, et al. Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants. Ann Med 2021; 53: 1227-1242.
33. HEP Drug Interactions. University of Liverpool. Available at https://hep-druginteractions.org/checker (accessed: 01.08.2025).
34. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021; 23: 1612-1676.
35. Gelosa P, Castiglioni L, Tenconi M, et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res 2018; 135: 60-79.
36. Lund M, Petersen TS, Dalhoff KP. Clinical implications of P-glycoprotein modulation in drug-drug interactions. Drugs 2017; 77: 859-883.
37. Garrison KL, Kirby B, Stamm LM, et al. Drug-drug interaction profile of sofosbuvir/velpatasvir/voxilaprevir fixed-dose combination. J Hepatol 2017; 66: S492-S493.
38. Bellesini M, Bianchin M, Corradi C, et al. Drug-drug interactions between direct oral anticoagulants and hepatitis C direct-acting antiviral agents: Looking for evidence through a systematic review. Clin Drug Investig 2020; 40: 1001-1008.
39. Hanigan S, Das J, Pogue K, Barnes GD, et al. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis 2020; 49: 636-643.
40. Boyle A, Davidson K, Cassidy C, et al. Management strategies for drug-drug interactions between direct oral anticoagulants and hepatitis C directly acting agents: A multicentre review. J Hepatol 2019; 70 (SA1): E216-217.
41. Trusz-Gluza M. Stosowanie leków przeciwkrzepliwych niebędących antagonistami witaminy K (NOAC) u chorych z migotaniem przedsionków Przewodnik European Heart Rhythm Association 2021. Med Prakt 2021; 12: 34-49.
42. Collet JP, Roffi M, Byrne RA, et al. Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC); ESC Scientific Document Group; Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC). Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. Eur Heart J 2018; 39: e1-e33.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.